Orthosteric Binding of ρ-Da1a, a Natural Peptide of Snake Venom Interacting Selectively with the α1A-Adrenoceptor

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Maïga, Arhamatoulaye ^a   Merlin, Jon ^b   Marcon, Elodie ^a   Rouget, Céline ^a   Larregola, Maud ^a   Gilquin, Bernard ^a   Fruchart Gaillard, Carole ^a   Lajeunesse, Evelyne ^a   Marchetti, Charles ^c   Lorphelin, Alain ^c   Bellanger, Laurent ^c   Summers, Roger J ^b   Hutchinson, Dana S ^b   Evans, Bronwyn A ^b   Servent, Denis ^a   Gilles, Nicolas ^a  

^a SERVICE DE CHIMIE BIOORGANIQUE ET DE MARQUAGE   (France)

^b MONASH UNIVERSITY   (Australia)

^c DIF   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2 [2 (4 HYDROXYPHENYL)ETHYLAMINOMETHYL]TETRALONE; 2 [2 (4 HYDROXYPHENYL)ETHYLAMINOMETHYL]TETRALONE I 125; ALPHA 1A ADRENERGIC RECEPTOR; CALCIUM; IMIDAZOLINE; PARA DA1A TOXIN; PHENETHYLAMINE; PRAZOSIN; RADIOLIGAND; SNAKE VENOM; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; BINDING KINETICS; BINDING SITE; CALCIUM TRANSPORT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISSOCIATION; DRUG ACTIVITY; DRUG BINDING; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; EQUILIBRIUM CONSTANT; EUKARYOTIC CELL; HUMAN; IC 50; MUTATIONAL ANALYSIS; NONHUMAN; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN TARGETING; SITE DIRECTED MUTAGENESIS; TOXIN ANALYSIS;

ADRENERGIC ALPHA-1 RECEPTOR AGONISTS; ADRENERGIC ALPHA-1 RECEPTOR ANTAGONISTS; ANIMALS; BINDING SITES; BINDING, COMPETITIVE; CHO CELLS; CRICETULUS; ELAPID VENOMS; ELAPIDAE; HUMANS; KINETICS; LIGANDS; MODELS, MOLECULAR; MUTATION; PRAZOSIN; PROTEIN BINDING; RADIOLIGAND ASSAY; RECEPTORS, ADRENERGIC, ALPHA-1; TETRALONES;

EID: 84880831220     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0068841     Document Type: Article

References (57)

1. Escoubas P, King GF, (2009) Venomics as a drug discovery platform. Expert Rev Proteomics 6: 221-224.
2. Halai R, Craik DJ, (2009) Conotoxins: natural product drug leads. Nat Prod Rep 26: 526-536.
3. Lewis RJ, Garcia ML, (2003) Therapeutic potential of venom peptides. Nat Rev Drug Discov 2: 790-802.
4. Shen GS, Layer RT, McCabe RT, (2000) Conopeptides: From deadly venoms to novel therapeutics. Drug Discov Today 5: 98-106.
5. Maïga A, Mourier G, Quinton L, Rouget C, Gales C, et al. (2012) G protein-coupled receptors, an unexploited animal toxin targets: Exploration of green mamba venom for novel drug candidates active against adrenoceptors. Toxicon 59: 487-496.
6. Servent D, Fruchart-Gaillard C, (2009) Muscarinic toxins: tools for the study of the pharmacological and functional properties of muscarinic receptors. J Neurochem 109: 1193-1202.
7. Sharpe IA, Thomas L, Loughnan M, Motin L, Palant E, et al. (2003) Allosteric alpha 1-adrenoreceptor antagonism by the conopeptide rho-TIA. J Biol Chem 278: 34451-34457.
8. Rajagopalan N, Pung YF, Zhu YZ, Wong PT, Kumar PP, et al. (2007) Beta-cardiotoxin: a new three-finger toxin from Ophiophagus hannah (king cobra) venom with beta-blocker activity. Faseb J 21: 3685-3695.
9. Quinton L, Girard E, Maiga A, Rekik M, Lluel P, et al. (2010) Isolation and pharmacological characterization of AdTx1, a natural peptide displaying specific insurmountable antagonism of the alpha(1A)-adrenoceptor. Br J Pharmacol 159: 316-325.
10. Rouget C, Quinton L, Maiga A, Gales C, Masuyer G, et al. (2010) Identification of a novel snake peptide toxin displaying high affinity and antagonist behaviour for the alpha2-adrenoceptors. Br J Pharmacol 161: 1361-1374.
11. Fruchart-Gaillard C, Mourier G, Marquer C, Menez A, Servent D, (2006) Identification of various allosteric interaction sites on M1 muscarinic receptor using 125I-Met35-oxidized muscarinic toxin 7. Mol Pharmacol 69: 1641-1651.
12. Fruchart-Gaillard C, Mourier G, Marquer C, Stura E, Birdsall NJ, et al. (2008) Different interactions between MT7 toxin and the human muscarinic M1 receptor in its free and N-methylscopolamine-occupied states. Mol Pharmacol 74: 1554-1563.
13. Marquer C, Fruchart-Gaillard C, Letellier G, Marcon E, Mourier G, et al. (2011) Structural Model of Ligand-G Protein-coupled Receptor (GPCR) Complex Based on Experimental Double Mutant Cycle Data: MT7 SNAKE TOXIN BOUND TO DIMERIC hM1 MUSCARINIC RECEPTOR. Journal of Biological Chemistry 286: 31661-31675.
14. Mourier G, Dutertre S, Fruchart-Gaillard C, Menez A, Servent D, (2003) Chemical synthesis of MT1 and MT7 muscarinic toxins: critical role of Arg-34 in their interaction with M1 muscarinic receptor. Mol Pharmacol 63: 26-35.
15. Waelbroeck M, De Neef P, Domenach V, Vandermeers-Piret MC, Vandermeers A, (1996) Binding of the labelled muscarinic toxin 125I-MT1 to rat brain muscarinic M1 receptors. Eur J Pharmacol 305: 187-192.
16. Olianas MC, Adem A, Karlsson E, Onali P, (2004) Action of the muscarinic toxin MT7 on agonist-bound muscarinic M1 receptors. European Journal of Pharmacology 487: 65-72.
17. Kukkonen A, (2004) Muscarinic Toxin 7 Selectivity Is Dictated by Extracellular Receptor Loops. Journal of Biological Chemistry 279: 50923-50929.
18. Ragnarsson L, Wang CI, Andersson A, Fajarningsih D, Monks T, et al. (2013) Conopeptide rho-TIA Defines a New Allosteric Site on the Extracellular Surface of the alpha1B-Adrenoceptor. J Biol Chem 288: 1814-1827.
19. Lima V, Mueller A, Kamikihara SY, Raymundi V, Alewood D, et al. (2005) Differential antagonism by conotoxin rho-TIA of contractions mediated by distinct alpha1-adrenoceptor subtypes in rat vas deferens, spleen and aorta. Eur J Pharmacol 508: 183-192.
20. Evans BA, Broxton N, Merlin J, Sato M, Hutchinson DS, et al. (2011) Quantification of functional selectivity at the human alpha(1A)-adrenoceptor. Mol Pharmacol 79: 298-307.
21. Cheng Y, Prusoff WH, (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22: 3099-3108.
22. Christopoulos A, Parsons AM, Lew MJ, El-Fakahany EE, (1999) The assessment of antagonist potency under conditions of transient response kinetics. Eur J Pharmacol 382: 217-227.
23. Lew MJ, Angus JA, (1995) Analysis of competitive agonist-antagonist interactions by nonlinear regression. Trends Pharmacol Sci 16: 328-337.
24. Lew MJ, Angus JA, (1997) An improved method for analysis of competitive agonist/antagonist interactions by non-linear regression. Ann N Y Acad Sci 812: 179-181.
25. Sali A, Blundell TL, (1993) Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol 234: 779-815.
26. Horn F, Bettler E, Oliveira L, Campagne F, Cohen FE, et al. (2003) GPCRDB information system for G protein-coupled receptors. Nucleic Acids Res 31: 294-297.
27. Vroling B, Sanders M, Baakman C, Borrmann A, Verhoeven S, et al. (2011) GPCRDB: information system for G protein-coupled receptors. Nucleic Acids Res 39: D309-319.
28. Cherezov V, Rosenbaum DM, Hanson MA, Rasmussen SG, Thian FS, et al. (2007) High-Resolution Crystal Structure of an Engineered Human {beta}2-Adrenergic G Protein Coupled Receptor. Science 318: 1258-1265.
29. King GF, Gentz MC, Escoubas P, Nicholson GM, (2008) A rational nomenclature for naming peptide toxins from spiders and other venomous animals. Toxicon 52: 264-276.
30. Avlani V, (2003) Application of a Kinetic Model to the Apparently Complex Behavior of Negative and Positive Allosteric Modulators of Muscarinic Acetylcholine Receptors. Journal of Pharmacology and Experimental Therapeutics 308: 1062-1072.
31. Mohr K, Trankle C, Holzgrabe U, (2003) Structure/activity relationships of M2 muscarinic allosteric modulators. Receptors Channels 9: 229-240.
32. Leppik RA, Mynett A, Lazareno S, Birdsall NJ, (2000) Allosteric interactions between the antagonist prazosin and amiloride analogs at the human alpha(1A)-adrenergic receptor. Mol Pharmacol 57: 436-445.
33. Hamaguchi N, True TA, Saussy DL Jr, Jeffs PW, (1996) Phenylalanine in the second membrane-spanning domain of alpha 1A-adrenergic receptor determines subtype selectivity of dihydropyridine antagonists. Biochemistry 35: 14312-14317.
34. Cavalli A, Fanelli F, Taddei C, De Benedetti PG, Cotecchia S, (1996) Amino acids of the alpha1B-adrenergic receptor involved in agonist binding: differences in docking catecholamines to receptor subtypes. FEBS Lett 399: 9-13.
35. Takahashi K, Hossain M, Ahmed M, Bhuiyan MA, Ohnuki T, et al. (2007) Asp125 and Thr130 in transmembrane domain 3 are major sites of alpha1b-adrenergic receptor antagonist binding. Biol Pharm Bull 30: 1891-1894.
36. Ahmed M, Hossain M, Bhuiyan MA, Ishiguro M, Tanaka T, et al. (2008) Mutational analysis of the alpha 1a-adrenergic receptor binding pocket of antagonists by radioligand binding assay. Biol Pharm Bull 31: 598-601.
37. Waugh DJ, Zhao MM, Zuscik MJ, Perez DM, (2000) Novel aromatic residues in transmembrane domains IV and V involved in agonist binding at alpha(1a)-adrenergic receptors. J Biol Chem 275: 11698-11705.
38. Hwa J, Perez DM, (1996) The unique nature of the serine interactions for alpha 1-adrenergic receptor agonist binding and activation. J Biol Chem 271: 6322-6327.
39. Chen S, Xu M, Lin F, Lee D, Riek P, et al. (1999) Phe310 in transmembrane VI of the alpha1B-adrenergic receptor is a key switch residue involved in activation and catecholamine ring aromatic bonding. J Biol Chem 274: 16320-16330.
40. Hwa J, Graham RM, Perez DM, (1995) Identification of critical determinants of alpha 1-adrenergic receptor subtype selective agonist binding. J Biol Chem 270: 23189-23195.
41. Waugh DJ, Gaivin RJ, Zuscik MJ, Gonzalez-Cabrera P, Ross SA, et al. (2001) Phe-308 and Phe-312 in transmembrane domain 7 are major sites of alpha 1-adrenergic receptor antagonist binding. Imidazoline agonists bind like antagonists. J Biol Chem 276: 25366-25371.
42. Wetzel JM, Salon JA, Tamm JA, Forray C, Craig D, et al. (1996) Modeling and mutagenesis of the human alpha 1a-adrenoceptor: orientation and function of transmembrane helix V sidechains. Receptors Channels 4: 165-177.
43. Shim JY, Bertalovitz AC, Kendall DA, (2011) Identification of essential cannabinoid-binding domains: structural insights into early dynamic events in receptor activation. J Biol Chem 286: 33422-33435.
44. Palea S, Maiga A, Guilloteau V, Rekik M, Guerard M, et al. (2012) Effects of rho-Da1a a peptidic alpha1a-adrenoceptor antagonist in human isolated prostatic adenoma and anesthetized rats. Br J Pharmacol in press.
45. Perret BG, Wagner R, Lecat S, Brillet K, Rabut G, et al. (2003) Expression of EGFP-amino-tagged human mu opioid receptor in Drosophila Schneider 2 cells: a potential expression system for large-scale production of G-protein coupled receptors. Protein Expression and Purification 31: 123-132.
46. Grunewald S, Haase W, Molsberger E, Michel H, Reilender H, (2004) Production of the Human D2S Receptor in the Methylotrophic Yeast P. pastoris? Receptors and Channels 10: 37-50.
47. Kenakin T, (2005) New concepts in drug discovery: collateral efficacy and permissive antagonism. Nat Rev Drug Discov 4: 919-927.
48. Kenakin T, Miller LJ, (2010) Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery. Pharmacol Rev 62: 265-304.
49. Compeer MG, Meens MJ, Hackeng TM, Neugebauer WA, Holtke C, et al. (2012) Agonist-dependent modulation of arterial endothelinA receptor function. Br J Pharmacol 166: 1833-1845.
50. Lazareno S, Birdsall NJ, (1995) Detection, quantitation, and verification of allosteric interactions of agents with labeled and unlabeled ligands at G protein-coupled receptors: interactions of strychnine and acetylcholine at muscarinic receptors. Mol Pharmacol 48: 362-378.
51. Strader CD, Sigal IS, Register RB, Candelore MR, Rands E, et al. (1987) Identification of residues required for ligand binding to the beta-adrenergic receptor. Proc Natl Acad Sci U S A 84: 4384-4388.
52. Porter JE, Hwa J, Perez DM, (1996) Activation of the alpha1b-adrenergic receptor is initiated by disruption of an interhelical salt bridge constraint. J Biol Chem 271: 28318-28323.
53. Palczewski K, Kumasaka T, Hori T, Behnke CA, Motoshima H, et al. (2000) Crystal structure of rhodopsin: A G protein-coupled receptor. Science 289: 739-745.
54. Hanson MA, Roth CB, Jo E, Griffith MT, Scott FL, et al. (2012) Crystal structure of a lipid G protein-coupled receptor. Science 335: 851-855.
55. Wu B, Chien EY, Mol CD, Fenalti G, Liu W, et al. (2010) Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science 330: 1066-1071.
56. Avlani VA, Gregory KJ, Morton CJ, Parker MW, Sexton PM, et al. (2007) Critical role for the second extracellular loop in the binding of both orthosteric and allosteric G protein-coupled receptor ligands. J Biol Chem 282: 25677-25686.
57. Koivula K, Rondinelli S, Näsman J, (2010) The three-finger toxin MTα is a selective α2B-adrenoceptor antagonist. Toxicon 56: 440-447.